Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL
Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara. Importantly, advanced–stage, second-line CLL patients receiving FluCAM more than doubled the amount of time without disease progression in comparison to patients receiving Fludara alone. Based on the study’s positive preliminary findings, Genzyme intends to seek regulatory approvals to further broaden the Campath label to include the use of this combination regimen.
Following a planned second interim analysis, the CAM314 trial’s data safety monitoring panel recommended early closure of the study as it had achieved the pre-specified clinical and statistical significance in progression free survival (PFS), the study’s primary endpoint. While patients in the study continue to be followed, and final efficacy and safety data from the study are expected to be available in the second-half of 2010, response data from the second interim analysis (as assessed by the study’s investigators) reported at ASH indicate that the FluCAM combination provided significantly higher overall and complete response rates compared to Fludara alone. The preliminary results also suggest that the FluCAM regimen has an acceptable safety profile when compared to single-agent Fludara.
With a median of 17 months of follow up at the time of the second interim analysis, and as assessed by the independent data safety monitoring panel (IRRP), the FluCAM arm demonstrated superior progression free survival in comparison to Fludara alone, with median PFS of 29.6 months on the FluCAM regimen compared to 20.7 months for patients on Fludara, reducing the risk of disease progression or death by 39 percent (p=0.005). Of particular note, in the pre-specified subgroup of patients with advanced, Rai stage III-IV CLL, the median PFS was 26.1 months for FluCAM and 12.1 months for Fludara (p=0.003).
In addition, according to clinical trial investigator assessments, the FluCAM regimen provided significantly higher overall and complete response rates. The overall response rate of patients on FluCAM was 84.8 percent compared to 67.9 percent on Fludara (p<0.001). The complete response rate was 30.4 percent on FluCAM versus 16.4 percent on Fludara (p=0.002).
An additional secondary endpoint, overall survival, did not reach significance at this interim analysis.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Dietary fibre powers the multivitamin factory in your gut - Luxembourg Institute of Health reveals critical link between fibre intake, gut bacteria, B vitamins and immune health
Tarceva helps patients with genetically distinct form of lung cancer live longer - Phase II study points to importance of EGFR biomarker to identify patients who can gain exceptional survival benefits
TSUBAME supercomputer predicts cell-membrane permeability of cyclic peptides
Mechanism of dengue virus entry into cells
Gene that improves quality of reprogrammed stem cells identified by Singapore scientists - Provides 'a better inkling of what we might aim for before differentiating iPS cells to clinically useful cell types'
One synthetic molecule, two doorways into cell
Vasa_praevia
Chemists create eco-friendly method to make chlorine-based materials for drugs and chemicals - “Our method uses sustainable, low-cost catalysts and operates at room temperature with gentle blue light”
Tick genome reveals inner workings of a resilient blood-guzzler
New study on optimizing microbial fuel cells shows electrode material can make all the difference
Bacteria block transmission of Zika and Dengue viruses
